Category Archives: Cancer Patients

Dr. David Samadi Says Surgery Over Prostate Radiation Is Better

The burden of prostate cancer in society is substantial and has increased since the PSA testing was introduced, but patients often question should you go with surgery or radiation to treat this disease. Dr. David Samadi, leading expert and Chairman of Urology at Lenox Hill Hospital dedicated a full show on his morning radio broadcast, and has a Youtube video discussing the benefits of surgery vs radiation.There are various alternative therapies available for the treatment. Depending on the stage of the disease, surgery, radiotherapy, and in some cases, simply waiting may be used. Especially in older patients, postponing the treatment to a later date is a possible alternative. For patients it is often not easy to decide on a therapy. Especially between surgery and radiotherapy, many factors often influence the decision-making process, but Dr. David Samadi says surgery is by far a better choice than radiation.

Several studies have examined both procedures and concluded that between surgery and radiotherapy, there was a clear benefit to operation versus radiotherapy. Dr. Samadi addressed this question on his radio broadcast, and he remarked that “with surgery, the outcome is great…and radiation should be considered a Plan B.”Also with surgery, there is a shorter recovery time. Doctors also note that when treating a prostate carcinoma, there are also different stages that may require a different treatment method. Family history also plays a role in determining the best treatment method. It appears that prostate cancer patients with family history may have a worse outcome after treatments by radiotherapy prostatectomy compared with patients without a family history.Genetic factors are also responsible in 5 to 10 percent of prostate cancer cases, and in this scenario, patients often opt for surgery.

The hardship of prostate cancer will increase due to our aging population.A clear understanding of risk factors, including factors like family history, race, and aging, and diet and environmental agents will help design strategies for the best treatment, not to mention diminish risk.Dr. David Samadi has been researching and treating urological diseases like prostate cancer for nearly two decades. Born in Iran, Dr. Samadi and his family immigrated to the United States where he attended high school then Stony Brook University in New York. After earnin his Bachelor’s and Medical degrees he completed his residency at local New York hospitals.Dr. Samadi developed the groundbreaking SMART surgery technique, and today is a internationally recognized surgeon, based in New York where he heads the Urology department at Lenox Hill Hospital.

Clay Siegall Is The Driving Force For Helping Cancer Patients

Highly motivated to develop and expand cancer therapies, cancer research pioneer Clay Siegall has worked tirelessly to achieve advancements in inventive therapies for cancer patients.

Since co-founding Seattle Genetics in 1998, Siegall has almost twenty years in guiding the company to new scientific achievements. He is the current president, chief executive officer and chairman of the board of Seattle Genetics.

Siegall’s intense enthusiasm and passion have made it easier for him to lead the company to undertake new levels of research development.

Under his direction the company has built a diverse channel of antibody-based cancer therapies through its proprietary, industry leading technology.

Specifically, Seattle Genetics has built up its antibody-drug conjugate (ADC) technology that brings into play antibodies or other biologics produced by a single cell that transports highly active pharmaceutical ingredients to targeted cells.

ADCs, including the company’s first ADC product ADCETRIS, is now available in more than 60 countries.

Seattle Genetics has entered into many collaborations for its ADC technology including with companies such as GlaxoSmithKline, Pfizer, Genentech (Roche) and others.

Aside from his success in the new cancer therapy line of work, Siegall has proven his impact through his fundraising expertise.

For example, he has led Seattle Genetics’ capital raising interests through private and public financings by securing more than $1.2 billion. And the company’s stock price has nearly tripled over a five year period.

Siegall, who holds 15 patents, has also published more than 70 scientific pieces of writing. He has been recognized for his scientific contributions with many awards including The University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences as well as the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year.

What’s more he is a board member of Mirna Therapeutics, Ultragenyx Pharmaceutical, Alder BioPharmaceuticals and Washington Roundtable.

Siegall graduated with a B.S. degree from the University of Maryland and went on to receive a Ph.D. from George Washington University. He started on his career as a senior research investigator at the Bristol-Myers Squibb Pharmaceutical Research Institute.